Last reviewed · How we verify

sIPV+DTaP+HepA

China National Biotec Group Company Limited · FDA-approved active Biologic

sIPV+DTaP+HepA is a Combination vaccine Biologic drug developed by China National Biotec Group Company Limited. It is currently FDA-approved for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus.

This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens.

This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens. Used for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus.

At a glance

Generic namesIPV+DTaP+HepA
SponsorChina National Biotec Group Company Limited
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhaseFDA-approved

Mechanism of action

sIPV+DTaP+HepA is a pentavalent combination vaccine containing inactivated poliovirus vaccine (sIPV), diphtheria and tetanus toxoids with acellular pertussis vaccine (DTaP), and hepatitis A virus antigen. It stimulates humoral and cellular immune responses to prevent infection by these five pathogens. The vaccine works by presenting antigens that trigger B and T cell responses, leading to production of protective antibodies and memory immunity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sIPV+DTaP+HepA

What is sIPV+DTaP+HepA?

sIPV+DTaP+HepA is a Combination vaccine drug developed by China National Biotec Group Company Limited, indicated for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus.

How does sIPV+DTaP+HepA work?

This combination vaccine provides immunization against poliomyelitis, diphtheria, tetanus, pertussis, and hepatitis A through inactivated viral and bacterial antigens.

What is sIPV+DTaP+HepA used for?

sIPV+DTaP+HepA is indicated for Prevention of poliomyelitis, Prevention of diphtheria, Prevention of tetanus, Prevention of pertussis, Prevention of hepatitis A.

Who makes sIPV+DTaP+HepA?

sIPV+DTaP+HepA is developed and marketed by China National Biotec Group Company Limited (see full China National Biotec Group Company Limited pipeline at /company/china-national-biotec-group-company-limited).

What drug class is sIPV+DTaP+HepA in?

sIPV+DTaP+HepA belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is sIPV+DTaP+HepA in?

sIPV+DTaP+HepA is FDA-approved (marketed).

What are the side effects of sIPV+DTaP+HepA?

Common side effects of sIPV+DTaP+HepA include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness.

Related